Pulse Biosciences, Inc.

PLSE

$52.69

Updated: 23/09/2026, 10:31:29

Market Cap

$3.65B

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Country

Stock valuation chart

One-year closing share-price history for PLSE

Company Profile

Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.

USD

NASDAQ

CEO: Paul Arthur LaViolette

Employees: 116

https://www.pulsebiosciences.com

Asset Summaries

Latest generated summaries for PLSE

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for PLSE.

Share price: $52.69
Market cap: $3.65B
Exchange: NASDAQ
Currency: USD
CEO: Paul Arthur LaViolette
Employees: 116
IPO date: 18/05/2016
Beta: 1.625
Last dividend: $0.00
Day range: $52.50 – $53.66
52-week range: $12.56 – $58.90
1-day performance: -1.16%
1-year performance: 319.51%
Current drawdown (1Y): -10.54%
CIK: 0001625101
CUSIP: 74587B101
ISIN: US74587B1017
Created: 07/12/2025, 05:47:04
Last update: 23/09/2026, 10:31:29

Track Pulse Biosciences, Inc. with an AI analyst

See which prediction-market events move PLSE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to PLSE from your Railway `news_articles` table.

Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 10/06/2026, 20:12:24

Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy

Zacks Investment Research • STOCK • 26/05/2026, 15:00:30

Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Seeking Alpha • STOCK • 13/05/2026, 23:30:43

Pulse Biosciences Q1 Earnings Call Highlights

MarketBeat • STOCK • 08/05/2026, 18:16:02

Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 08/05/2026, 02:01:39

Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research • STOCK • 04/05/2026, 11:06:10

Pulse Biosciences, Inc. (PLSE) Shareholder/Analyst Call Transcript

Seeking Alpha • STOCK • 25/04/2026, 22:41:31

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Business Wire • STOCK • 25/04/2026, 15:00:00

Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study

Zacks Investment Research • STOCK • 13/04/2026, 12:51:26

Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference

Business Wire • STOCK • 02/04/2026, 18:05:00

PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data

Zacks Investment Research • STOCK • 26/03/2026, 14:05:46

Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript

Seeking Alpha • STOCK • 20/02/2026, 03:54:58